Clay B. Siegall, Ph.D.

President, Chief Executive Officer and Chairman of the Board

Clay co-founded Seagen in 1998 with a vision to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs. A scientist by training, he built a foundation based on a unique science-driven culture, successful drug discovery and development, and a passion for helping patients. Today, Seagen has three FDA-approved medicines and leads the field in antibody–drug conjugate (ADC) technology and development.

Year joined:

1997 as co-founder


Bristol-Myers Squibb Pharmaceutical Research Institute

National Institutes of Health, National Cancer Institute


University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences

Pacific Northwest Ernst & Young Entrepreneur of the Year

Dealmaker of the Year by the Puget Sound Business Journal


Author on more than 70 publications

Holds 15 patents


Ph.D., Genetics, George Washington University

B.S., Zoology, University of Maryland


Director, Ultragenyx Pharmaceutical

Director, Washington Roundtable

Roger D. Dansey, M.D.

Chief Medical Officer

Roger has served as our Chief Medical Officer since May 2018, bringing extensive experience in cancer drug development. Previously, he was with Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. His deep oncology background and proven leadership had helped us become a global, multi-product oncology company.

Year joined:



Senior Vice President, Merck Inc.
Led late-stage oncology development efforts, including the approved PD-1 inhibitor, KEYTRUDA®, 2015-2018

Vice President, Oncology Clinical Research, Gilead Sciences. 2013-2014

Various roles of increasing responsibility, Amgen
Oncology and hematology therapeutic areas, including Global Development Leader for XGEVA®


M.D., University of Witwatersrand, Johannesburg, South Africa

Vaughn B. Himes, Ph.D.

Chief Technical Officer

Vaughn has more than 30 years of product development and commercialization experience at large pharmaceutical and biotechnology companies. With deep operational expertise, he leads manufacturing, supply chain, process sciences, and quality functions for Seattle Genetics. Vaughn has played a pivotal role in the successful commercialization of our marketed products and the development of our robust pipeline of product candidates.

Year joined:


Other positions held:

Executive Vice President, Technical Operations and Process Science 
Executive Vice President, Technical Operations 


Senior Vice President, Technical Operations –ZymoGenetics (later acquired by Bristol Myers Squibb)
Commercial and clinical manufacturing, supply chain and logistics, quality control and process development

Experience cont.:
Other biotech leadership roles

10 years in the pharmaceutical industry with Wyeth, now Pfizer


Ph.D, Chemical Engineering, University of Minnesota

B.A., Chemistry, Pomona College

Todd E. Simpson

Chief Financial Officer

Todd brought his extensive industry experience in senior financial positions with public biotechnology companies to his role as our CFO. He’s leveraged that experience to grow our Finance and Facilities groups to accommodate the company’s continuing growth. Our campus and finance systems are well-positioned for fulfilling our mission.

Year joined:



Vice President, Finance and Administration and Chief Financial Officer, Targeted Genetics, 2001-2005

Vice President, Finance and Administration and Chief Financial Officer, Aastrom Biosciences, 1996-2001

Integra Life Sciences Corporation, 1995

Telios Pharmaceuticals, Inc. (acquired by Integra in 1995)

Ernst & Young LLP, 1983-1992 with a focus in life sciences and technology practices


Certified Public Accountant (inactive)

B.S., Accounting and Computer Science, Oregon State University


Neoleukin Therapeutics, Inc. (Chairman of the Board)

Jean I. Liu, J.D.

General Counsel, Executive VP, Legal Affairs

Jean oversees all aspects of the company’s legal, compliance and intellectual property functions and serves as Corporate Secretary. Her experience allows her to partner with management on the highest level of corporate strategic matters.

Year joined:



Vice President and General Counsel, Halozyme

Chief Legal Officer and Corporate Secretary and other roles, Durect Corporation

Pillsbury, Madison & Sutro (now Pillsbury Winthrop), Venture Law Group
Legal advising for early stage companies, including technology transfer, licensing, patents and copyright and trademark litigation


J.D, Columbia University
Harlan Fiske Stone Scholar

M.S., Biology, Stanford University

B.S., Cellular and Molecular Biology with highest distinction, University of Michigan

Christopher Pawlowicz

Executive VP, Human Resources

Chris has more than 30 years of human resources experience, principally in the pharmaceutical industry.

Year joined:


Other positions held:

Senior Vice President, Human Resources


Senior Vice President, Human Resources and Administration, MedPointe Pharmaceuticals
Part of the turnaround team that successfully restructured and sold the business to Meda Pharmaceuticals

Experience cont.:

Corporate Vice President, Human Resources, Express Scripts
The nation’s third largest pharmacy benefit management company

Senior human resources positions at Pharmacia, Searle and Monsanto
Global launch of Celebrex, the start-up of biotechnology teams in plant sciences, support of high growth commercial investments in Latin America, Europe and Asia, and post-merger integration of numerous companies


M.A., Labor and Industrial Relations, University of Illinois at Urbana-Champaign

B.A., Economics, Benedictine College, summa cum laude

Nancy Whiting, Pharm.D.

Executive VP, Late Stage Development

Nancy has broad experience in drug development and medical affairs. Since joining Seattle Genetics, she has made many contributions to the company, including driving the development strategy for ADCETRIS and tucatinib, and providing important scientific contributions to all our programs. 

Year joined:


Other positions held:

Senior Vice President, Development and Medical Affairs and Elliott Bay Site Head

Vice President, Medical Affairs

Executive Director, Medical Affairs 

Senior Medical Director, Experimental Medicine


Seattle Cancer Care Alliance
 - Clinical Oncology Pharmacist


Pharm.D., University of Washington

Residency in clinical pharmacy practice, Vancouver General Hospital

B.Sc. (Pharm), University of British Columbia


American Society of Clinical Oncology

American Society of Hematology 

European Society of Medical Oncology

Charles (Chip) Romp

Executive VP, Commercial

Chip leads our U.S. and Canadian Commercial organization and has over 27 years of biotechnology and pharmaceutical experience. Since joining Seattle Genetics to build our original ADCETRIS sales team, he has consistently provided decisive leadership, clear direction, and fostered a team culture that is true to our patient-centered values. Chip has continued to deliver strong results with the expansion our portfolio to three brands, ADCETRIS, PADCEV, and TUKYSA.

Year joined:


Other positions held:

Senior Vice President, Sales

Vice President, Sales


Genentech (member of the Roche Group)
- National Sales Director for Avastin
- National Sales Director for Rituxan
- Senior sales leadership positions for oncology and immunology products, including Rituxan (rituximab) and Xolair (omalizumab), and project lead for deployment of Genentech’s BioOncology sales forces

Product Manager at GE Medical Systems

Pharmaceutical sales representative, Sankyo Park Davis and GlaxoSmithKline


M.B.A., Saint Leo University (formerly Saint Leo College), Florida

B.A., University of Florida

Tuomo P├Ątsi

Executive VP, Commercial International

Tuomo joined us in July 2020 to lead our new Commercial organization in Europe, Canada and rest of world outside the U.S. He brings deep international commercial expertise with broad experience in scaling up commercial teams and launching multiple oncology drugs.

Year joined:



-President Worldwide Markets hematology/oncology business,
2017-2019; Bristol Myers Squibb Integration Lead,

-President Europe, Middle East and Africa region, 2014-2017

-Corporate Vice President, South Europe, Middle East and Africa, 2012-2014

Various roles of increasing responsibility at Human Genome Sciences, Amgen, Eli Lilly


M. Sc., Helsinki University, School of Pharmacy

Rachel Lenington

Senior VP, Program and Portfolio Management

Rachel brings over 20 years of diverse leadership and management experience from a variety of sectors including global public health and biotech to her leadership of our portfolio strategy, partnerships and global product development efforts.  She leverages this experience to advance and deliver on corporate, portfolio and product strategies and support Seattle Genetics’ transition to a global, multi-product oncology company.

Year joined:


Other positions held:

Vice President, Program, Portfolio and Alliance Management

Global Product Leader, ADCETRIS


Bill & Melinda Gates Foundation, responsible for the strategy and business operations of the Malaria and Neglected Infectious Diseases programs and leading alliances with product development organizations and country Ministries of Health

Experience cont.:

Amgen, drove the successful global development and commercialization strategy for Prolia® (denosumab)

Accenture and Deloitte Consulting, management consulting for clients such as Microsoft, Hewlett-Packard, Immunex, Sprint and Starbucks


M.B.A., Pepperdine University

B.A., Business, University of Washington

Natasha Hernday

Senior VP, Corporate Development

Natasha has broad experience in business and corporate development including in-licensing, out-licensing, venture capital and mergers and acquisitions. Since joining Seattle Genetics, she has successfully executed numerous technology licensing and platform deals with major pharma partners. She was instrumental in the acquisitions of our manufacturing facility, as well as bringing tucatinib and tisotumab vedotin into our pipeline.

Year joined:


Other positions held:

Vice President, Business Development


- Senior member of mergers and acquisitions team in corporate development
- Lead for out-licensing efforts
- Roles in research, research project management and business development finance


M.B.A., Pepperdine University

B.A., Biology, University of California Santa Barbara

Director, PDL BioPharma, Inc.

Member, External Advisory Board for the University of Oregon’s Knight Campus for Accelerating Scientific Impact